The biotech company is developing CapioCyte™, an advanced platform for capturing circulating tumor cells (CTCs) from whole blood. By utilizing biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte offers superior sensitivity compared to existing platforms. It also provides enriched CTCs for molecular analysis, such as FISH, RNA-Seq, and NGS. CapioCyte serves as a valuable tool for cancer research and has potential applications in clinical patient management. The company's personalized treatment therapies use liquid biopsy to remove cancer cells without altering them, empowering healthcare providers to provide optimal care.